Navigation Links
Microfluidic device with artificial arteries measures drugs' influence on blood clotting
Date:3/24/2014

A new microfluidic method for evaluating drugs commonly used for preventing heart attacks has found that while aspirin can prevent dangerous blood clots in some at-risk patients, it may not be effective in all patients with narrowed arteries. The study, which involved 14 human subjects, used a device that simulated blood flowing through narrowed coronary arteries to assess effects of anti-clotting drugs.

The study is the first to examine how aspirin and another heart attack prevention drug respond to a variety of mechanical blood flow forces in healthy and diseased arteries. Patients' blood was tested in a patent-pending microfluidic device with narrow passageways to simulate the coronary arteries. The data are consistent with clinical findings showing that physiology has a major influence on the effectiveness of drugs used for heart attack prevention.

The researchers believe that a benchtop diagnostic device like the one used in this study could save lives by preventing heart attacks and help lower healthcare costs by giving physicians better guidance on how drugs may affect individual patients.

"Doctors have many drug options and it is difficult for them to determine how well each of those options is going to work for a patient," said Melissa Li, who was a graduate student at the Georgia Institute of Technology at the time of the study. "This study is the first time that a prototype benchtop diagnostic device has tried to address this problem using varying shear rates and patient dosing and tried to make it more personalized."

The study was sponsored by the American Heart Association, a Wallace H. Coulter Foundation Translational Grant and by a fellowship from the Technological Innovation: Generating Economic Results (TI:GER) program at Georgia Tech. The study was published in a recent edition of the journal PLOS ONE.

About 10 percent of the U.S. population takes drugs every day because they are at risk o
'/>"/>

Contact: Brett Israel
brett.israel@comm.gatech.edu
404-385-1933
Georgia Institute of Technology
Source:Eurekalert  

Page: 1 2 3 4

Related biology news :

1. Engineers use droplet microfluidics to create glucose-sensing microbeads
2. UT Arlington engineer wins NSF award to support microfluidic analyses of tissue, cell samples
3. Microfluidic platform gives a clear look at a crucial step in cancer metastasis
4. Global Surgical Devices Market Growth Driven by Improving Standards of Living and Longer Life Expectancies, Research Shows
5. Medical device, health professionals attend first national conference on value-driven engineering
6. NJIT professor awarded patent today for new desalination devices, more
7. Tattoo-like devices for wireless pregnancy monitoring
8. Nowhere to hide: New device sees bacteria behind the eardrum
9. Pilot Results Move GHX Closer to Delivery of Healthcare Industrys First Implantable Device Supply Chain Solution
10. A millimeter-scale, wirelessly powered cardiac device
11. Medical devices powered by the ear itself
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Microfluidic device with artificial arteries measures drugs' influence on blood clotting
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
(Date:1/22/2015)... 2015 , Europe,s ... The European Patent Office to present a video retrospective of the ... be featured: Christofer Toumazou and Sophie Wilson   ... winners of the Award   Starting on 22 January ...
(Date:1/22/2015)... Inc. , a market leader of iris-based identity authentication solutions, ... the new role of Senior Vice President of Mobile and ... platforms and wearable solutions for EyeLock,s technologies. Gerber brings more ... industry to his role at EyeLock, with expertise in human ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... PITTSBURGH, Feb. 4 Researchers at the University ... $5.6 million federal contract to pursue the continued development ... and small children with congenital or acquired heart disease. ... sophisticated technologies that have saved the lives of older ...
... that the hydrodynamic environment of fish can shape their physical ... Journal of Experimental Biology Web site, was sponsored by ... Catch a glimpse of a fish,s body shape, and you ... look as if they should outpace frilly reef fish and ...
... energy habits and provide immediate feedback on consumption could ... compromising comfort. The new energy-saving ,Wattbox, device is ... improvements supported by a 2.1 million grant from the ... As well as working with standard energy supplies, the ...
Cached Biology News:Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 2Pitt-led team gets $5.6 million contract for heart assist device for infants and toddlers 3Research finds water movements can shape fish evolution 2Habit-learning device will lower energy bills under new clean energy cashback scheme 2
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:1/22/2015)... PRINCETON, N.J. , Jan. 22, 2015  Derma ... tissue regeneration company focused on advanced wound care, ... from placental tissues, have been added to the ... announcement increases the opportunity for the AMNIOEXCEL® and ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... DUBLIN and PHILADELPHIA , June 3, ... specialty biopharmaceutical company,announces that its subsidiary Shire LLC has filed a lawsuit ... Anchen Pharmaceuticals,Inc. and Anchen, Inc. (collectively "Anchen") for the infringement of U.S.,Patent ... patent). , , , ...
... , -Proceeds to support acceleration of CYT387 Phase II myelofibrosis study- , ... MISSISSAUGA, ON , June 3 ... raised approximately US$3.2 million through a non-brokered private placement of 2,500,000 ... at no discount to the closing price of the shares on the NYSE ...
... , , , ... Endpoints , , , ... Agency in,2010 , , , ... reproductive medicine, announces positive Phase III data from its,second pivotal study (PEARL I) for its lead product ...
Cached Biology Technology:INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 2INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc. 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 2YM BioSciences raises US$3.2 million in support of JAK 1/2 program 3YM BioSciences raises US$3.2 million in support of JAK 1/2 program 4PregLem Announces Positive Phase III Results for Esmya(TM) 2PregLem Announces Positive Phase III Results for Esmya(TM) 3PregLem Announces Positive Phase III Results for Esmya(TM) 4